Evidence map›Paper›PMID 29120819›Full record

ArticleBiomaterials2018

Towards a defined ECM and small molecule based monolayer culture system for the expansion of mouse and human intestinal stem cells.

Zhixiang Tong, Keir Martyn, Andy Yang, Xiaolei Yin, Benjamin E Mead, Nitin Joshi, Nicholas E Sherman, Robert S Langer, Jeffrey M Karp

Abstract read
In one paragraph

Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Zhixiang TongDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States.
Keir MartynDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States.
Andy YangDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States.
Xiaolei YinDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States; David H. Koch Institute for Integrative Cancer Research at MIT, United States.
Benjamin E MeadDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States; Broad Institute of Harvard and MIT, United States; David H. Koch Institute for Integrative Cancer Research at MIT, United States.
Nitin JoshiDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States.
Nicholas E ShermanDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States.
Robert S LangerHarvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States; Department of Chemical Engineering at MIT, United States; David H. Koch Institute for Integrative Cancer Research at MIT, United States.
Jeffrey M KarpDivision of BioEngineering in Medicine, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, United States; Harvard Medical School, United States; Harvard Stem Cell Institute, United States; Harvard - Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, United States. Electronic address: jeffkarp.bwh@gmail.com.
Brigham and Women's Hospital · USHarvard–MIT Division of Health Sciences and Technology · USHarvard Stem Cell Institute · USHarvard University · USMassachusetts Institute of Technology · US

Funding

PHOTOPOLYMERIZATION FOR NONINVASIVE CARTILAGE TISSUER01DE013023 · NIDCR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 1998 to 2019
$6.8M
Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
NHLBI NIH HHS R01 HL095722NIDCR NIH HHS R01 DE013023
6 · The paper itself

Abstract

Current ISC culture systems face significant challenges such as animal-derived or undefined matrix compositions, batch-to-batch variability (e.g. Matrigel-based organoid culture), and complexity of assaying cell aggregates such as organoids which renders the research and clinical translation of ISCs challenging. Here, through screening for suitable ECM components, we report a defined, collagen based monolayer culture system that supports the growth of mouse and human intestinal epithelial cells (IECs) enriched for an Lgr5

Indexed as

AnimalsCell Culture TechniquesCell ProliferationCoated Materials, BiocompatibleCollagenCollagen Type IVDrug CombinationsEpithelial CellsExtracellular MatrixGreen Fluorescent ProteinsHumansIntestinesLamininMice, Inbred C57BLProteoglycansPyrazolesCoated Materials, BiocompatibleCollagenCollagen Type IVDrug CombinationsGreen Fluorescent ProteinsLamininLDN 193189Lgr5 protein, mousematrigelProteoglycansPyrazolesPyrimidinesReceptors, G-Protein-CoupledBLT sandwich cultureIntegrin α2β1Intestinal stem cellsLgr5

Identifiers

PMID29120819
PMCPMC5735007
OpenAlexW2765964788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.